In situ Protein Detection for Companion Diagnostics.

Gremel G, Grannas K, Sutton LA, Pontén F, Zieba A

Front Oncol 3 (-) 271 [2013-10-31; online 2013-10-31]

The emergence of targeted therapies for cancer has created a need for the development of companion diagnostic tests. Assays developed in recent years are aimed at determining both the effectiveness and safety of specific drugs for a defined group of patients, thus, enabling the more efficient design of clinical trials and also supporting physicians when making treatment-related decisions. Immunohistochemistry (IHC) is a widely accepted method for protein expression analyses in human tissues. Immunohistochemical assays, used to localize and quantitate relative protein expression levels within a morphological context, are frequently used as companion diagnostics during clinical trials and also following drug approval. Herein, we describe established immunochemistry-based methods and their application in routine diagnostics. We also explore the possibility of using IHC to detect specific protein mutations in addition to DNA-based tests. Finally, we review alternative protein binders and proximity ligation assays and discuss their potential to facilitate the development of novel, targeted therapies against cancer.

Tissue Profiling

PubMed 24199171

DOI 10.3389/fonc.2013.00271

Crossref 10.3389/fonc.2013.00271

pmc: PMC3814083

Publications 9.5.0